Sheaff Brock Investment Advisors LLC bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,600 shares of the biopharmaceutical company’s stock, valued at approximately $961,000.
Several other hedge funds have also recently bought and sold shares of the business. Nan Fung Group Holdings Ltd increased its position in Madrigal Pharmaceuticals by 380.7% during the first quarter. Nan Fung Group Holdings Ltd now owns 5,682 shares of the biopharmaceutical company’s stock worth $1,517,000 after buying an additional 4,500 shares during the last quarter. EntryPoint Capital LLC bought a new stake in Madrigal Pharmaceuticals during the first quarter valued at about $41,000. Propel Bio Management LLC boosted its holdings in Madrigal Pharmaceuticals by 43.3% during the first quarter. Propel Bio Management LLC now owns 43,032 shares of the biopharmaceutical company’s stock valued at $11,491,000 after acquiring an additional 13,000 shares during the period. Pitcairn Co. bought a new stake in Madrigal Pharmaceuticals during the first quarter valued at about $269,000. Finally, Vanguard Group Inc. boosted its holdings in Madrigal Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,668,806 shares of the biopharmaceutical company’s stock valued at $445,638,000 after acquiring an additional 94,064 shares during the period. 98.50% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on MDGL shares. Cantor Fitzgerald restated a “neutral” rating on shares of Madrigal Pharmaceuticals in a report on Tuesday. HC Wainwright decreased their price target on shares of Madrigal Pharmaceuticals from $425.00 to $390.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Bank of America began coverage on shares of Madrigal Pharmaceuticals in a report on Monday, April 22nd. They set an “underperform” rating and a $150.00 price target for the company. JMP Securities increased their target price on shares of Madrigal Pharmaceuticals from $381.00 to $385.00 and gave the company a “market outperform” rating in a research note on Tuesday, July 16th. Finally, Wolfe Research began coverage on shares of Madrigal Pharmaceuticals in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $382.00 target price for the company. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $348.50.
Insider Transactions at Madrigal Pharmaceuticals
In related news, Director Fred B. Craves sold 22,489 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $212.88, for a total value of $4,787,458.32. Following the completion of the sale, the director now owns 413,362 shares of the company’s stock, valued at $87,996,502.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Fred B. Craves sold 22,489 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $212.88, for a total value of $4,787,458.32. Following the completion of the sale, the director now owns 413,362 shares of the company’s stock, valued at $87,996,502.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Robert E. Waltermire sold 1,036 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $231.34, for a total transaction of $239,668.24. Following the completion of the transaction, the vice president now directly owns 5,500 shares in the company, valued at $1,272,370. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,425 shares of company stock valued at $6,129,127. Corporate insiders own 23.92% of the company’s stock.
Madrigal Pharmaceuticals Price Performance
MDGL traded up $1.03 during midday trading on Friday, reaching $284.49. 167,769 shares of the company’s stock were exchanged, compared to its average volume of 488,499. The firm has a market capitalization of $6.06 billion, a price-to-earnings ratio of -12.28 and a beta of -0.42. The company has a quick ratio of 9.39, a current ratio of 9.39 and a debt-to-equity ratio of 0.14. Madrigal Pharmaceuticals, Inc. has a one year low of $119.76 and a one year high of $299.98. The business has a 50-day simple moving average of $264.94 and a two-hundred day simple moving average of $243.55.
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($7.38) EPS for the quarter, missing analysts’ consensus estimates of ($6.06) by ($1.32). During the same period in the previous year, the company posted ($4.23) EPS. As a group, research analysts predict that Madrigal Pharmaceuticals, Inc. will post -27.7 EPS for the current year.
Madrigal Pharmaceuticals Profile
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
See Also
- Five stocks we like better than Madrigal Pharmaceuticals
- Why is the Ex-Dividend Date Significant to Investors?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What Do S&P 500 Stocks Tell Investors About the Market?
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Want to see what other hedge funds are holding MDGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report).
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.